Compare Stocks

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APS Aptose Biosciences	C$1.73 -1.1%	C$2.20	C$1.71 ▼ C$11.40	C$27.18M	1.44	8,785 shs	2,200 shs
ONCR Oncorus	$0.13 -3.1%	$0.07	$0.01 ▼ $0.47	$3.29M	3.6	1.33 million shs	135,900 shs
SPRB Spruce Biosciences	$0.70 +0.0%	$2.84	$0.68 ▼ $5.95	$28.85M	2.52	1.13 million shs	249,171 shs
SQZ SQZ Biotechnologies	$0.05	$0.05	$0.25 ▼ $3.56	$1.48M	2.34	455,220 shs	2,050 shs

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APS Aptose Biosciences	0.00%	-7.89%	-12.94%	-40.27%	+157.35%
ONCR Oncorus	0.00%	0.00%	0.00%	0.00%	-61.82%
SPRB Spruce Biosciences	-0.74%	-8.19%	-6.35%	-70.67%	-66.93%
SQZ SQZ Biotechnologies	0.00%	+7.07%	+3.63%	+11.11%	-99.25%

New crypto project uncovers 2,050% in 65 days (Ad)

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APS Aptose Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ONCR Oncorus	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SPRB Spruce Biosciences	2.7722 of 5 stars	4.1	3.0	0.0	0.0	0.0	2.5	1.3
SQZ SQZ Biotechnologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APS Aptose Biosciences	N/A	N/A	N/A	N/A
ONCR Oncorus	N/A	N/A	N/A	N/A
SPRB Spruce Biosciences	2.25	Hold	$5.67	708.14% Upside
SQZ SQZ Biotechnologies	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest SQZ, ONCR, SPRB, OXB, and APS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/14/2024	SPRB Spruce Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$8.00 ➝ $3.00
3/14/2024	SPRB Spruce Biosciences	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
3/14/2024	SPRB Spruce Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
3/14/2024	SPRB Spruce Biosciences	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$9.00 ➝ $2.00
3/14/2024	SPRB Spruce Biosciences	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$9.00 ➝ $2.00
3/14/2024	SPRB Spruce Biosciences	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
3/14/2024	SPRB Spruce Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
3/5/2024	SPRB Spruce Biosciences	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$9.00
2/26/2024	SPRB Spruce Biosciences	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$8.00 ➝ $9.00
2/21/2024	SPRB Spruce Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APS Aptose Biosciences	N/A	N/A	C$1.08 per share	1.60	C$1.03 per share	N/A
ONCR Oncorus	N/A	N/A	N/A	N/A	$2.33 per share	N/A
SPRB Spruce Biosciences	$10.09M	2.86	N/A	N/A	$1.88 per share	0.37
SQZ SQZ Biotechnologies	$18.16M	0.08	N/A	N/A	$1.94 per share	0.03

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APS Aptose Biosciences	-C$51.21M	-C$10.49	N/A	∞	N/A	N/A	-225.00%	-102.23%	5/13/2024 (Estimated)
ONCR Oncorus	-$77.42M	-$3.49	N/A	∞	N/A	N/A	N/A	N/A	N/A
SPRB Spruce Biosciences	-$47.92M	-$1.25	N/A	N/A	N/A	-474.96%	-52.31%	-39.77%	5/20/2024 (Estimated)
SQZ SQZ Biotechnologies	-$79.46M	-$2.61	N/A	N/A	N/A	-369.96%	-119.83%	-59.90%	N/A

Latest SQZ, ONCR, SPRB, OXB, and APS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/26/2024	Q4 2023	APS Aptose Biosciences	-C$1.98	-C$1.96	+C$0.02	-C$1.96	N/A	N/A
3/13/2024	Q4 2023	SPRB Spruce Biosciences	-$0.41	-$0.23	+$0.18	-$0.23	$1.65 million	$2.89 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APS Aptose Biosciences	N/A	N/A	N/A	N/A	N/A
ONCR Oncorus	N/A	N/A	N/A	N/A	N/A
SPRB Spruce Biosciences	N/A	N/A	N/A	N/A	N/A
SQZ SQZ Biotechnologies	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APS Aptose Biosciences	14.27	0.78	5.41
ONCR Oncorus	N/A	N/A	N/A
SPRB Spruce Biosciences	0.02	4.18	4.18
SQZ SQZ Biotechnologies	N/A	3.50	3.50

Ownership

Institutional Ownership

Company	Institutional Ownership
APS Aptose Biosciences	9.80%
ONCR Oncorus	20.07%
SPRB Spruce Biosciences	91.71%
SQZ SQZ Biotechnologies	38.51%

Insider Ownership

Company	Insider Ownership
APS Aptose Biosciences	20.20%
ONCR Oncorus	17.10%
SPRB Spruce Biosciences	9.10%
SQZ SQZ Biotechnologies	16.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
APS Aptose Biosciences	31	15.71 million	N/A	Not Optionable
ONCR Oncorus	64	26.09 million	21.63 million	Optionable
SPRB Spruce Biosciences	29	41.15 million	37.41 million	Optionable
SQZ SQZ Biotechnologies	53	29.49 million	24.77 million	Not Optionable

SQZ, ONCR, SPRB, OXB, and APS Headlines

Source	Headline
	VC funding update: who raised money in March? bizjournals.com - April 1 at 11:06 AM
	SQZ, Portal founder Armon Sharei on starting over in biotech biopharmadive.com - March 26 at 10:35 AM
	Portal Biotechnologies Announces $5M Pre-Seed Round Led By Pear VC finance.yahoo.com - March 19 at 10:20 AM
	SQZ, months after 80% layoffs, opts for liquidation and $11.8M asset fire sale to Stemcell fiercebiotech.com - March 1 at 10:56 AM
	Rx Rundown: Gilead Sciences, Latigo Biotherapeutics, Exscientia and more mmm-online.com - February 16 at 8:05 AM
	SQZB SQZ Biotechnologies Company seekingalpha.com - December 28 at 1:42 PM
	SQZ Biotechnologies Co Ordinary Shares SQZB morningstar.com - December 12 at 8:37 PM
	SQZ founder Armon Sharei opens Portal to to simplify intracellular delivery fiercebiotech.com - December 12 at 10:35 AM
	'Medicine at a bigger scale': FUJIFILM Diosynth Biotechnologies unveils new Holly Springs drug manufacturing site wral.com - November 11 at 8:41 PM
	‘Difficult but necessary steps’: SQZ lays off 80% of staff, RegenXBio cuts 15% fiercebiotech.com - November 9 at 10:34 AM
	SQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio Updates finance.yahoo.com - November 8 at 6:33 PM
	SQZ Biotechnologies GAAP EPS of -$0.80 misses by $0.30, revenue of $0M msn.com - November 8 at 6:33 PM
	Lifeline Biotechnologies Inc LLBO morningstar.com - November 4 at 11:41 PM
	SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting finance.yahoo.com - November 3 at 7:42 PM
	SQZ Biotechnologies Reports Second Quarter 2023 Financial Results and Recent Portfolio Updates finance.yahoo.com - August 10 at 9:16 PM
	Sqz Biotechnologies Co (SQZB) investing.com - August 3 at 7:45 AM
	Roche declines to take up option on SQZ Bio’s SQZ-APC-HPV program thepharmaletter.com - July 27 at 12:11 AM
	Roche Passes on Option to Advance Cell Therapy in HPV-Positive Tumors With SQZ Biotechnologies precisionmedicineonline.com - July 25 at 10:53 PM
	Roche Decides Not to Exercise Solid Tumor Option with SQZ biospace.com - July 25 at 10:53 PM
	SQZ Biotechnologies Provides Update on Collaboration with Roche benzinga.com - July 25 at 12:37 PM
	Roche snubs SQZ HPV 16 programme, leaving the beleaguered company in the lurch pharmaceutical-technology.com - July 25 at 12:37 PM
	Understanding the Risks of Investing in SQZ Biotechnologies Company (SQZ) knoxdaily.com - July 5 at 1:10 PM
	SQZ Biotechnologies to be delisted from the NYSE seekingalpha.com - July 3 at 11:23 PM
	NYSE to Commence Delisting Proceedings Against SQZ Biotechnologies Company (SQZ) finance.yahoo.com - July 3 at 6:23 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aptose Biosciences

TSE:APS

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Oncorus

NASDAQ:ONCR

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company develops ONCR-021 for the treatment of non-small cell lung cancer, renal cell carcinoma, melanoma, and anaplastic thyroid cancer; and ONCR-788 for the treatment of small cell lung cancer, neuroendocrine prostate, and other neuroendocrine cancers. Oncorus, Inc. was incorporated in 2015 and is headquartered in Andover, Massachusetts.

Spruce Biosciences

NASDAQ:SPRB

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.

SQZ Biotechnologies

NYSE:SQZ

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial